Saturday 17 October 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023. In the quarter to June 2026, revenue fell 57.1%, EPS grew 71.9%, free cash flow grew 25.3% and total debt rose 1.54%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.55
2.61
−62.74%
Follow GUTS
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 20.88 | 9.90 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 174.00 | 36.36 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 94 | 102 | 107 | 100 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | 0 | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | 35.83 | 46.24 | — | |||||
| EBT | — | — | — | — | — | — | (46) | (77) | (69) | (141) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | (64,242.50) | (73,864.52) | 0.00 | |||||
| Net income | — | — | — | — | — | — | (46) | (77) | (69) | (141) | |||||
| Depreciation | — | — | — | — | — | — | 0 | 0 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.06 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (23.34) | (45.29) | (1.62) | (1.86) | |||||
| Cash flow | — | — | — | — | — | — | (23.24) | (20.58) | (1.50) | (1.19) | |||||
| Capex | — | — | — | — | — | — | (0.03) | (0.17) | (0.04) | (0.01) | |||||
| Free cash flow | — | — | — | — | — | — | (23.27) | (20.75) | (1.55) | (1.20) | |||||
| Book value | — | — | — | — | — | — | (126.79) | (156.20) | 0.65 | 0.12 | |||||
| Shares, m | — | — | — | — | — | — | 2 | 2 | 44 | 76 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | — | 2,701.07 | 11,573.74 | — | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 37.87 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 2,881.30 | 11,172.65 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | (8.01) | (15.44) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (46) | (43) | (66) | (90) | ||||
| Capex | — | — | — | — | — | — | 0 | 0 | (2) | (1) | |||||
| Free cash flow | — | — | — | — | — | — | (46) | (43) | (67) | (91) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 44 | 24 | 52 | 69 | ||||
| Total debt | — | — | — | — | — | — | 18 | 55 | 30 | 31 | |||||
| Net debt | — | — | — | — | — | — | (32) | 22 | (37) | (51) | |||||
| Shareholders’ equity | — | — | — | — | — | — | (252) | (325) | 28 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (137.45) | (74.55) | (122.85) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | 32.65 | 46.32 | (744.17) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Dec 2024
Charts ten years each
Fractyl Health, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CNTB Connect Biopharma Holdings Limited Sponsored ADR | $57.1M | — (loss-making) | — (loss-making) | +296.56% (above 0%: growing) | n/m | −23.48% (below 0%: shrinking) | 100.00% | (635.98%) | Compare |
| TENX Tenax Therapeutics, Inc. | $56.5M | — (loss-making) | — | −77.98% (below 0%: shrinking) | n/m | −125.93% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $56.4M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | Compare |
| ELOX Senesco Technologies Inc. | $55.3M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| GUTS Fractyl Health, Inc. | $55.2M | — (loss-making) | — (loss-making) | −57.14% (below 0%: shrinking) | n/m | +25.34% (above 0%: growing) | 100.00% | 0.00% | |
| GOSS Gossamer Bio, Inc. | $54.3M | — (loss-making) | — (loss-making) | −19.59% (below 0%: shrinking) | n/m | +16.32% (above 0%: growing) | 100.00% | (282.25%) | Compare |
| RNTX Rein Therapeutics Inc. | $54.2M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +115.40% (above 0%: growing) | n/m | −27.63% (below 0%: shrinking) | 84.27% | (368.43%) | Compare |
| BOLD Boundless Bio, Inc. | $53.5M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $54.8M | — | — | +47.91% | — | −31.12% | 92.14% | 0.00% |
Fractyl Health, Inc. (GUTS) key facts
- Concern: Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Fractyl Health, Inc. (GUTS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, GUTS traded at $1.55, a market capitalization of $55.2 million.
- Return on equity was −744.2% and debt-to-equity -18.29.
- Its Altman Z-score is 0.45 (distress zone) for fiscal 2024.